- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc stock price live, this page displays NASDAQ LXRX stock exchange data. View the LXRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lexicon Pharmaceuticals Inc real time stock price chart below.
What Is the Lexicon Pharmaceuticals Inc Stock Price Today?
The Lexicon Pharmaceuticals Inc stock price today is 1.230.
What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?
The stock symbol for Lexicon Pharmaceuticals Inc is "LXRX."
What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?
Lexicon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Lexicon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Lexicon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LXRX quote. (ISIN: US5288723027)
What Is the Lexicon Pharmaceuticals Inc Stock Price Today?
The Lexicon Pharmaceuticals Inc stock price today is 1.230.
What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?
The stock symbol for Lexicon Pharmaceuticals Inc is "LXRX."
What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?
Lexicon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Lexicon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Lexicon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LXRX quote. (ISIN: US5288723027)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.200
1.270
52 wk Range
0.284
1.830
LXRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.2001.270
52 wk Range
0.2841.830
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LXRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
2.920
Upside
+137.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Tesla, AMD among market cap stock movers on Friday
- Investing.com
- Tesla, AMD among market cap stock movers on Friday
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Lexicon Pharmaceuticals Inc Company Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- Lexicon Pharmaceuticals exceeded Q3 2025 forecasts with EPS of -$0.04 vs. -$0.07 expected and revenue of $14.2M vs. $4.65M projected, driving a 6.16% pre-market stock increase
- Revenue surged from $1.8M in Q3 2024 to $14.2M, primarily due to a $13.2M licensing deal with Novo Nordisk, while net loss decreased to $12.8M from $64.8M year-over-year
- The company maintains a strong cash position of $145M and projects full-year 2025 operating expenses between $105M-$115M
- Lexicon plans to resubmit Zingquista for type 1 diabetes in 2026 and continues the Sonata study for sotagliflozin in hypertrophic cardiomyopathy
- CEO Mike Exton highlighted the company's strategic shift to focus on R&D, with efforts to include both obstructive and non-obstructive patients in future product labels
Last Updated: 2025-11-06, 10:34 a/m
Read Full TranscriptCompare LXRX to Peers and Sector
Metrics to compare | LXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLXRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.7x | 1.1x | −0.5x | |
PEG Ratio | −0.10 | 0.05 | 0.00 | |
Price/Book | 4.4x | 7.7x | 2.6x | |
Price / LTM Sales | 7.4x | 8.6x | 3.3x | |
Upside (Analyst Target) | 70.7% | 298.4% | 45.7% | |
Fair Value Upside | Unlock | 11.0% | 6.5% | Unlock |
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2.920
(+137.40% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.04 / -0.07
Revenue / Forecast
14.10M / 4.65M
People Also Watch
FAQ
What Is the Lexicon (LXRX) Stock Price Today?
The Lexicon stock price today is 1.230
What Stock Exchange Does Lexicon Trade On?
Lexicon is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lexicon?
The stock symbol for Lexicon is "LXRX."
What Is the Lexicon Market Cap?
As of today, Lexicon market cap is 525.31M.
What Is Lexicon's Earnings Per Share (TTM)?
The Lexicon EPS (TTM) is -0.19.
When Is the Next Lexicon Earnings Date?
Lexicon will release its next earnings report on Mar 18, 2026.
From a Technical Analysis Perspective, Is LXRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Lexicon Stock Split?
Lexicon has split 1 times.
How Many Employees Does Lexicon Have?
Lexicon has 103 employees.
What is the current trading status of Lexicon (LXRX)?
As of Feb 08, 2026, Lexicon (LXRX) is trading at a price of 1.230, with a previous close of 1.180. The stock has fluctuated within a day range of 1.200 to 1.270, while its 52-week range spans from 0.284 to 1.830.
What Is Lexicon (LXRX) Price Target According to Analysts?
The average 12-month price target for Lexicon is USD2.920, with a high estimate of USD6 and a low estimate of USD1. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +137.40% Upside potential.
What Is the LXRX Premarket Price?
LXRX's last pre-market stock price is 1.219. The pre-market share volume is 17,910.000, and the stock has decreased by 0.039, or 3.310%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.